Stocks · News reference
Repligen Raises FY2026 Adj EPS Guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 Est; Raises FY2026 Sales Guidance from $803.000M-$833.000M to $813.000M-$835.000M vs $822.537M Est
Repligen (NASDAQ:RGEN) raises FY2026 Adj EPS guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 analyst estimate. Raises FY2026 sales outlook from $803.000 million-$833.000 million to $813.000 million-$835.000 million vs
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 28, 2026, 11:01 AM
- Checked
- Jul 28, 2026, 11:01 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
JP Morgan Maintains Overweight on Repligen, Raises Price Target to $175
Read original at benzingaNasdaq 100 Enters Correction, SanDisk Sinks Over 50% From Peak: Stock Market Today
A deepening chip rout drags the Nasdaq while Coca-Cola and Sherwin-Williams beats power the Dow; oil dives 5% on Iran diplomacy as the Fed meets.
Read original at benzinga12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular session. The company's market cap stands at $936.3 million. As per the press release, Q2 earnings came out yesterday.
Read original at benzinga